Abstract. We have previously shown that peptides derived from the thrombospondin sequence, CSVTCG, promoted tumor cell adhesion. To further investigate this observation, the CSVTCG-tumor cell adhesion receptor from A549 human lung adenocarcinoma cells was isolated and characterized. A single protein peak was isolated by CSVTCG affinity chromatography which also analyzed as a single peak by anion exchange chromatography. The purified protein had a pI of 4.7 and analyzed on SDS-gels as a single band of Mr = 50,000 under nonreducing conditions and as two protein bands of Mr = 50,000, and 60,000 under reducing conditions. Purified CSVTCG binding protein (CBP) bound either CSVTCG-or TSP-Sepharose but showed little interaction with either VCTGSC-or BSA-Sepharose. CBP was cell surface exposed. CSVTCG derivatized with [1251] Bolton-Hunter reagent was taken up by cells in a dose-dependent manner and the cell association was inhibited with a monospecific polyclonal anfi-CBP antibody. Examination of the cell proteins crosslinked to labeled CSVTCG by SDS-gel electrophoresis revealed one band that comigrated with purified CPB. Using an in vitro binding assay, purified CBP bound mannose, galactose, and glucosamine-specific lectins. CBP bound TSP saturably and reversibly. The binding was Ca+2/Mg +2 ion dependent and inhibited with fluid phase TSP and anti-CBP. Little or no binding was observed on BSA, fibronectin, GRGES, and GRGDS. Heparin, but not lactose, inhibited binding. Anti-CBP IgG and anti-CSVTCG peptide IgG inhibited A549 cell spreading and adhesion on TSP but not on fibronectin and laminin. These results indicate that CBP and the CSVTCG peptide domain of TSP can mediate TSP-promoted tumor cell adhesion.
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T HROMBOSPONDIN (TSP) 1 is a large multi-domain protein that was originally purified from platelets (15) but has since been found in many tissues including bone (23) , muscle (39) , skin (38, 39) , and brain (20) . A major physiological function of this protein appears to involve cell-extracellular matrix interaction because purified preparations of TSP promote cell-substratum interaction of a variety of cell types (34) , including platelets (30, 33) . Support for a role of TSP in matrix-cell interaction was demonstrated in a recent study by Arbeille et al. (3) who showed that TSP was localized in microfibrils at the junction between basement membrane and connective tissue in sections of human placenta, porcine arteries and skin. Additional support comes from several in vitro studies which show that TSP has a high binding affinity for components of the basement membrane such as collagen (8) , fibronectin (13) , and heparansulfate containing macromolecules (9) .
Recently, our group (32) and two others (21, 22) independently demonstrated that peptides containing the sequence VTCG promoted cell attachment. Rich et al. (22) showed that several peptides containing VTCG from region H of the circumsporozoite protein isolated from the malarial parasite Plasmodium vivax strongly promoted the attachment of T cells and myeloid cells. Prater et al. (21) showed that peptides containing VTCG and having sequences corresponding to amino acid residues 424-442 and 481-499 of TSP promoted G361 melanoma cell attachment. We demonstrated that peptides having the sequence CSVTCG and highly homologous analogues promoted the attachment of B16-F10 mouse melanoma, A549 human lung adenocarcinoma, bovine aortic endothelial cells and rabbit smooth muscle cells. These peptides also inhibited platelet aggregation and tumor cell metastasis presumably by competing with cell surface TSP receptors.
In this report we provide evidence that the anti-metastatic CSVTCG peptides bind tumor cell receptors that function as TSP tumor cell adhesion receptors. These receptors are distinct from known TSP receptors such as the integrins and may represent a new class of high affinity TSP receptors. These data also provide additional support for the hypothesis that TSP plays a major role in mediating tumor cell adhesive interactions.
Direct ELISA
ELISA assays were performed as previously described (36) . Briefly, microtiter plates were coated with 2 #g of protein either BSA, FN, TSP, or CSVTCG binding protein and blocked with 1% BSA for 1 h. Wells were incubated for 1 h with 50 #1 of various dilutions of the first antibody in 10 mM phosphate buffer, pH 7.4, containing 150 mM NaC1 and 0.05% Tween-20 (PBS-T). Wells were then washed three times in PBS-T and incubated for 1 h with 50 #1 of a 1:800 dilution in PBS-T of alkaline phosphatase coupled rabbit anti-goat IgG. Wells were washed three times with PBS-T followed with three washes of PBS-T buffer containing no Tween-20 and treated with 50 #1 of alkaline phosphatase substrate solution (1 mg/ml of p-nitrophenylphosphate in 0.10 M glycine, pH 10.4, containing 1 mM ZnC12 and 1 mM MgC12). After 30 min, color development was stopped by the addition of 5/tl of I N NaOH and absorbances determined at 405 nm.
Antibodies
CSVTCG was coupled to maleimide activated keyhole limpet hemocyanin (KLH) according to the instructions provided with the Pierce Imject Activated Immunogen Conjugation Kit, Pierce Chemical Co. Approximately 4 mg of peptide was coupled to 2 mg of KLH. A goat was injected subcutaneously with 1 nag of peptide-protein conjugate suspended in complete Freund's and boosted with two additional injections of 500 #g of peptideprotein conjugate in incomplete Freund's adjuvant three and 5 wk after the first injection. Goat immunization and collection of serum was accomplished commercially through Hazelton Research Products, Inc. (Denver, PA).
Polyclonal anti-CSVTCG was affinity purified on TSP-Sepharose. Briefly, IgG prepared by ammonium sulfate precipitation of 100 ml of antisera was dissolved in 50 ml of Hepes-buffered saline, pH 7.35 (column buffer), and passed over a 1 ml column of Sepharose containing 2 mg of coupled TSP. The TSP column was then washed with 10 ml of column buffer and eluted with 0.1 M sodium citrate buffer, pH 2.7. One ml fractions were collected in tubes containing 50 #1 of 1 M Tris base in order to neutralize the final solution. Protein fractions were pooled, concentrated and assessed for anti-TSP activity by ELISA analysis.
Polyclonal CSVTCG binding protein antiserum was raised in a rabbit after four 50 #g injections every 3-4 wk. The first injection was given with complete Freund's adjuvant and subsequent injections were administered with incomplete Freund's adjuvant. Rabbit immunization and collection of serum was accomplished commercially through Hazelton Research Products, Inc. Antibody titers and specificity were determined by ELISA.
TSP Purification
TSP was purified from Ca +2 ionophore A23187-activated human platelets as previously described (37) .
Protein Assays
Protein concentrations were determined by the bicinchoninic acid protein assay, adapted for microtiter plates, as described by Pierce Chemical Co. (Rockford, IL). BSA was used as standard.
Gel Electrophoresis
SDS-PAGE was performed using the Pharmacia Phast Gel or Biorad minislab gel systems. Protein samples were reduced with 5% beta-mercaptoethanol. Gels were silver stained, dried, and autoradiograms were prepared from the dried gels using intensifying screens (DuPont Cronex Lighting Plus screens mounted in Spectroline Cassettes, Reliance X-Ray Inc., Oretand, PA). Kodak X-Omat-AR film (Eastman Kodak Co., Rochester, NY) was used and developed according to the instructions provided with the film. Films were exposed for varying lengths of time at -70~
Protein and Cell Labeling
Purified CSVTCG-binding protein was labeled with [125I]iodine using Iodobeads as previously described (10) . Briefly, 12 #g of purified protein dissolved in 100 #1 of octylglucoside buffer was incubated with one Iodobead for 10 rain. Unreacted iodide was removed on a small column of Sephadex G-25 equilibrated in octylglucoside buffer as previously described (29) . The specific activity of protein obtained in a typical experiment was 0.5-2.0 x 10 4 cpm/ng. A549 cells were surface labeled with [1251]iodine using lactoperoxidase (29) . Briefly, celts from a 75-mm flask containing a near confluent monolayer of cells were harvested, washed, and suspended in 0.5 mi of DME containing 0.17 units/ml lactoperoxidase and 500 uCi of [12sI]-iodide. A 1 #1 aliquot of 0.002 % H202 in PBS was added with gentle mixing every minute for 4 rain. The iodination was then stopped by the addition of 600 #1 of 2 mM NaI in PBS, ceUs washed twice in PBS, and the pellet solubilized in NP-40 detergent as described below for purification of the CSVTCG binding protein.
Preparation of Coupled-Sepharose Gels for Specificity Experiments
Approximately 4 mg of either CSVTCG or VCTGSC or 2 nag of TSP or BSA were coupled to 1 ml of CN-activated Sepharose according to the instructions provided by Pharmacia LKB Biotechnology, Inc. Gels were equilibrated in 20 mM Tris HC1, pH 7.0, containing 1 mM CaC12, 1 mM MgCI2, and 5 mM octyt glucoside before use.
Preparation of pZq]-Bolton-Hunter Derivatized CSVTCG
A 100 #1 aliquot of 10 mg/ml solution of CSVTCG in PBS was added to 1 mCi of BoRon-Hunter reagent previously sparged with nitrogen to remove benzene as indicated in the instructions provided with the Bolton-Hunter kit. The reaction mixture was incubated with occasional shaking for 1 h at 4~ A 100 #1 aliquot of a 1 mg/mi glycine solution was then added to quench any unreacted reagent. The final reaction mixture was chromatographer on a 2-ml column of Sephadex (310 equilibrated in PBS containing 0.1% gelatin. The void volume peak (400 #1 containing 4.1 • 108 cpm) was collected and stored under nitrogen at 4aC until needed.
Cell Association and Cross-linking of [usI]-Bolton-Hunter Derivatized CSVTCG
A549 cells wore grown to near confluency in 6 well tissue culture plates. The media was then removed and cells rinsed twice with serum-free DME. Wells were treated with 1 ml serum-free media containing varying amounts of peptide (5 x 106 cprrdml in a typical experiment) for t h at 37*C. Monolayers were washed twice with PBS, harvested with EDTA and counted to determine cell-associated CSVTCG. For cross-linking, the washed monolayers were treated with 0.5 ml of a 2 mM BS 3 solution in PBS for 10 rain at room temperature, excess cross-linker removed, and the monolayer extracted with 100 p.l of SDS gel sample buffer containing 4 M urea, 1 mM EDTA, 1 mM PMSF, and 100/~1 leupeptin. The extracted cell layer was then analyzed by SDS-gel electrophoresis followed by autoradiography.
Purification of CSVTCG Binding Proteins
CSVTCG binding proteins were purified by affinity chromatography from A549 detergent extracts. Briefly, approximately 4.0 x 107 A549 cells were harvested with EDTA and the pellet washed once with DME. The cell pellet was then homogenized on ice with 5 rnl of solubilization buffer (10 mM Tris HC1, pH 7.5, containing 0.5% NP-40, 1 mM CaCI2, 1 mM MgC12, 100 t~M leupeptin, 1 mM phenylmethyl sulphonyl fluoride). The cell lysate was then centrifuged at 4"C for 20 min at 100,000 g to remove undissolved material. The supernatant was passed three times over a 5 ml column containing 4 nag of CSVTCG coupled to 1 ml of CN-activated Sepharose equilibrated in Hepes buffered saline, pH 7.35. The unbound material was washed with 20 ml of column buffer (10 mM Tris HC1, pH 7.5, containing 0.05 % NP-40, 1 mM CaC12, 1 mM MgC12, 100/~M leupeptin, 1 mM phenylmethyl sulphonyl fluoride). Bound material was eluted with elution buffer (0.1 M Tris, pH 10.2, containing 0.05% NP-40, 1 mM CaC12, 1 mM MgC12, 100/~M leupeptin, 1 mM phenylmethylsulphonyl fluoride) by collecting 1 ml fractions in a tube containing 70/~1 of 1 N HC1 to neutralize the final solution. The proteins eluting in the first 10 fractions were applied to an anion exchange column (Mono Q, Pharmacia LKB Biotechnology, Inc.) equilibrated in anion exchange column buffer (20 mM Tris HC1, pH 8.0, containing 5 mM octyl glucoside). The bound material was eluted at 0.7 ml/min with a 10 ml gradient of NaC1 (100% 1 M NaCI) and the column monitored at 280 and 260 nM. The bound material routinely began to elute at 0.3 M NaC1 and the gradient was held to allow the proteins to elute isocraticaily. The eluted fractions were concentrated and analyzed for TSP binding activity and further characterized by SDS-gel electrophoresis and isoelectric focusing. 
Binding Assay

Western Immunoblotting
Anti-CSTSCG antibody was characterized by Western immunoblotting using Pharmacia's Phast electrophoresis system. Whole cell extracts were prepared by dissolving 4 • 105 cells in 100/~1 of SDS sample buffer. Approximately, 100 ng of protein was separated under reducing conditions on an 8-25 % polyacrylamide gradient SDS gel. Gels were either silver stained or the proteins were electrophoretically transferred onto nitrocellulose paper. The paper was then blocked with 3 % BSA in PBS-T and treated for 1 h with either 1.37/~g/ml of ai~nity purified goat anti-CSVTCG or 50 /zg/ml anti-CSVTCG binding protein IgG for 1 h, washed with PBS-T, developed according to the instructions provided with the VECTASTAIN ABC immunoperoxidase system, (Vector Laboratories, Burlingame, CA). Controls were the respective control IgG fractions.
Results
Purification of CSVTCG Binding Protein
Approximately, 4.0 • 107 A549 cells were grown to near confluency and harvested with EDTA. The washed pellet was solubilized with NP-40 detergent and the extract applied to a CSVTCG-Sepharose column. One protein peak was eluted at high pH in the first 10 fractions as detected by SDS-gel Figure 1 . SDS-gel analysis of the high pH eluate from the CSVTCG affinity column. Detergent extracts of A549 cells were adsorbed on CSVTCG-Sepharose, unbound proteins washed, and bound proteins eluted at high pH. Fractions were analyzed under reducing conditions by SDS-gel electrophoresis on a 7.5 % polyacrylamide gel and visualized by silver staining. Lanes I and 8, tool standards; lanes 2-7, column fractions 1, 3, 5, 7, 9, and 10, respectively. electrophoresis under reducing conditions (Fig. 1) . This material could be adsorbed to an anion exchange column at pH 8 and eluted with 0.30 M NaCI as a single homogenous peak having a high ratio of absorbance at 260 to 280 nm (Fig.  2) . The purified material analyzed on SDS-gel electrophoresis as two polypeptide bands of Mr = 60,000 and 50,000 under reducing conditions and one polypeptide of Mr = 50,000 under nonreducing conditions (Fig. 3) . Analysis by isoelectric focusing revealed that the purified material resolved as one band with a pI in the range of 5.00-4.65 (Fig.  4) . Approximately, 100 #g of protein was recovered from 4 x 107 cells. and eluted from TSP and CSVTCG-coupled resins (Fig. 5 ).
Specificity of the Interaction of CSVTCG with the CSVTCG Binding Protein
In the second experiment, CSVTCG derivatized with p25I]-BoRon-Hunter reagent was added to monolayers of A549 cells in the presence and absence of anti-CSVTCG antibody and cross-linked with a water soluble cross-linking agent (Fig. 6 ). In the absence of antibody, CSVTCG became cellassociated in a dose-dependent manner, whereas in the presence of antibody cell-association was nearly completely inhibited (top inset, Fig. 6 ). Cross-linking of the derivatized CSVTCG to cells identified one major band that comigrated with the purified CSVTCG binding protein on SDS-gels (bottom inset, Fig. 6 ). These experiments indicate that the CSVTCG binding protein recognizes CSVTCG both in vitro and on the cell surface.
Characterization of CSVTCG Binding Protein
To characterize the CSVTCG binding protein, the protein was labeled with [~251]iodine and evaluated for its capacity to bind TSP. Analysis of the labeled material by SDS-gel electrophoresis followed by autoradiography revealed that the Mr = 60,000 polypeptide was predominantly labeled (Fig. 3) . The labeled CSVTCG binding protein bound TSP in a time-dependent manner which became time-indepen- MnC12 supported significantly less binding (Fig. 7) . Binding (55 % of maximal) was also observed in the presence of 1 mM EDTA (Fig. 7) . The CSVTCG binding protein had the greatest binding affinity for TSP whereas fibronectin, BSA, and the peptides GRGES and GRGDS had negligible binding activity (Fig. 8) . The CSVTCG binding protein bound TSP saturably with an apparent binding constant of 0.30 #M. The binding constant was estimated from the least squares fit of the data to a rectangular hyperbola (correlation coefficient of 0.994) assuming Mr --50,000 (Fig. 9 ). This binding was reversible because increasing concentrations of unlabeled protein added to the incubation mixture caused a dosedependent inhibition of binding (Fig. 9) . Incubation of CSVTCG binding protein with TSP and heparin in the fluid phase resulted in a 64 and 80 % inhibition of binding respectively, whereas BSA and lactose had no effect (Fig. 10) . These results indicate that the CSVTCG-binding protein can interact specifically with TSP in vitro and that binding may be mediated by CSVTCG-binding associated glycoconjugates. Consistent with this conclusion is the observation that the CSVTCG-binding protein contains carbohydrate. We found that the purified protein bound galactose-, mannose-, and galactosamine-specific lectins (Table I ). 
The Effect of Anti-CSVTCG Binding Protein and Anti-CSVTCG Peptide Antibody on Tumor CeU Adhesion
To investigate the importance of the CSVTCG-binding protein in mechanisms of TSP-promoted cell substratum adhesion, a polyclonal CSVTCG binding protein antiserum was raised in a rabbit and a polyclonal CSVTCG antiserum was Figure 8 . raised in a goat. The antibodies were monospecific as determined by direct ELISA (data not shown) and by immunoblot analysis (Fig. 11) . Anti-CSVTCG binding protein antibody specifically recognized the Mr = 60,000 subunit of purified CSVTCG binding protein and A549 cell extracts under reducing conditions (Fig. 11 A) . Anti-CSVTCG recognized the 180-kD subunit of TSP and a minor 160-kD degradation product (Fig. 11 B) . Both anti-CSVTCG and anti-CSVTCG binding protein IgG fractions almost completely inhibited A549 cell adhesion to TSP-coated surfaces but had no effect on cell adhesion to fibronectin or laminin (Fig. 12) . In addition, both anti-CSVTCG and anti-CSVTCG binding protein IgG nearly totally prevented cell spreading on TSP but had no effect on FN and laminin-mediated cell spreading (data not shown). These results strongly suggest that the CSV-TCG-binding protein functions as a TSP cell adhesion receptor and the TSP sequence, CSVTCG, functions as a tumor cell adhesive domain of TSE Consistent with this interpretation is the cell surface orientation of the CSVTCG-binding protein which could be labeled with [125I]iodine on intact cells (Fig. 3) . Binding was .performed in binding buffer containing either 10 #g/ml BSA, 10 #g/ml aSP, 100 /~g/ml lactose, 100/~g/ml heparin, 100 #g/ml rabbit. IgG, or 100 #g/ml anti-CBP. The 100% control for lactose, heparin and aSP was the amount bound in the presence of fluid phase BSA. The 100% control for anti-CBP was the amount bound in the presence of rabbit IgG. Values given were calculated from the mean of two duplicate determinations and are representative of a typical experiment. Duplicate values differed by no more than 5 %.
D i s c u s s i o n
A major focus of our work has been to show that TSP plays a significant role in the pathogenesis of tumor spread. Several lines of evidence both from our laboratory and from the work of others strongly suggest that TSP may mediate one or more steps in the metastatic cascade. We observed that mice injected with tumor cells together with TSP developed 2-3 times more lung metastases than did controls (27) . A likely explanation for these results is that TSP promoted the adhesion of tumor cells to the vessel wall because there were initially more tumor cells trapped in the lungs of the TSPtreated animals than in controls. In addition, the metastatic colonies in the TSP-treated animals were significantly larger than in the non-TSP treated animals suggesting that TSP may have had an effect on the growth and aggregate size of the cells. To determine whether high levels of circulating TSP could be playing a role in the pathogenesis of human cancer, plasma TSP levels of various cancer patients were measured. We found that patients with breast cancer, lung cancer, and colon cancer had circulating plasma TSP-levels two to threefold higher than normal controls or patients with noncancer illnesses (35) . Similar results were found for patients with myeloproliferative disorders (17) , and gynecologic malignancies (18) . TSP could not only promote the adhesion of these human tumors and thereby promote metastasis formation but also enhance the metastatic potential of these cells. The latter conclusion was supported by the study of Castle et al. (7) who showed that production of TSP by human squamous carcinoma tumors correlated with the expression of the malignant phenotype because the antisense reduction of TSP message resulted in tumors that were nonmetastatic, slow growing, and highly differentiated. Therefore, tumor cells may utilize both endogenously expressed TSP and plateletreleased TSP as anchors for attachment to the vascular basement membrane and as promoters of the malignant phenotype.
It is clear from a number of studies that TSP can bind to multiple cell surface receptors on the same cell or bind to different receptors on different cells. For example, platelets can bind TSP through GPIIb-IIIa (10, 30) , the vitronectinreceptor (14) , and GPIa-IIa (30) . Smooth muscle ceils (16) , endothelial cells (16), U937 monocyte-like cells (16) , and melanoma cells can bind TSP (28) through a vitronectin-like receptor. Squamous cell carcinoma cells bind TSP through an Mr = 80,000/105,000 protein that is not an integrin or GPIV (40) .
The involvement in TSP cell adhesive interactions of GPIV or CD36, originally described as a monocyte specific antigen (12) , remains controversial. Originally, Asch and colleagues (4) demonstrated that TSP binding to activated platelets, melanoma cells, and fibrosarcoma cells could be inhibited by a monoclonal antibody to GPIV, OKM5 (12) . These cells contained GPIV on their surfaces and isolated GPIV could be shown to bind TSP in vitro. However, Aiken et al. (1) could not block platelet surface TSP expression with anti-GPIV antibody and the analysis was further complicated by the fact that anti-GPIV caused platelet activation. Platelets deficient in GPIV bound TSP to the same extent as normal platelets suggesting that other platelet receptors were capable of binding TSP (11) . Anti-GPIV alone could not block TSP-mediated cell adhesion but did so weakly in the presence of high levels of heparin suggesting that GPIV is not a primary mediator of adhesion in this system despite the fact that previous in vitro assays performed by different groups show that isolated GPIV could bind TSP (2, 6) . Initial studies showing that GPIV mediated TSP-monocyte binding (24, 25) have recently been called into question because the same results could be obtained by measuring the binding of TSP to a calcium precipitate formed by the addition of CaC12 to the binding medium used in the initial studies (26) . Finally, two opposite results were obtained from GPIV transfection studies. Oquendo et al. (19) found that COS cells transfected with GPIV showed no difference in TSP binding compared to controls. In contrast, Asch et al. (5) found that Jurkat cells transfected with GPIV bound TSP saturably whereas control cells showed little or no binding. One difference in these transfection studies is the cell type used. COS cells are adherent cells and Jurkat cells are suspension cells. It would be interesting to know if the GPIV-transfected Jurkat cells became adherent especially on TSP-coated surfaces.
As described above, TSP plays a major role in cellular adhesion. We recently identified a TSP cell adhesion domain that consisted of the hexapeptide sequence, CSVTCG (32) . Synthetic CSVTCG peptides and homologous analogues promoted the adhesion of A549 lung carcinoma, B16-F10 melanoma cells, bovine aortic endothelial cells, and rabbit smooth muscle cells. These peptides inhibited platelet aggregation and the complex process of tumor cell metastasis which depends in part on TSP adhesive activity (27) . We postulated that the way these peptides inhibited platelet aggregation and tumor cell metastasis was to bind to cell surface receptors specific for CSVTCG and TSP and thereby compete for endogenous TSP adhesive interactions.
To test this hypothesis, CSVTCG A549 tumor cell binding proteins were isolated and characterized in an in vitro TSP binding and cell adhesion assay. Chromatography of A549 cell detergent extracts on a CSVTCG peptide affinity column yielded one tightly-bound protein peak that was eluted at high pH. The protein appeared homogenous because it could be eluted as a single peak from an anion exchange column and analyzed by isoelectric focusing as a homogeneous band having a pI of 4.7. The protein appeared to be glycosylated because it bound to galactose, glucosamine, and mannose specific lectins. Consistent with the presence of glycoconjugate was the high 260 nm absorbance of the purified protein and the capacity of heparin to inhibit the binding interaction between TSP. On SDS gels under reducing conditions, the protein migrated as two major polypeptide bands spaced closely together with apparent molecular weights of 60,000 and 50,000 kD. Under nonreducing conditions, a single band of 50,000 kD was observed but in some preparations small amounts of dimers could be observed with molecular weights >100,000 kD. These results are consistent with the interpretation that the protein consists of two interchain disulfide-linked polypeptide chains that assume a more compact configuration when disulfide bonded.
The CSVTCG binding protein is surface exposed in A549 cells because it could be labeled with [~25I]iodine on intact cells. In addition, a rabbit polyclonal antibody raised against the protein inhibited adhesion and spreading of A549 cells to TSP but not to fibronectin or laminin indicating that not only is the CSVTCG binding protein surface exposed but it is also functioning as a TSP adhesion receptor. Blockage of the ligand for the CSVTCG binding protein on TSP with anti-CSVTCG peptide antibody also inhibited TSP-promoted cell adhesion and spreading. These results suggest that cells utilize the CSVTCG-binding protein to adhere and spread on TSP-coated tissue culture plates.
To determine whether the CSVTCG could function as a receptor for TSP in vitro, labeled CSVTCG binding protein was evaluated for its capacity to bind TSP. We found that CSVTCG binding protein interacted with TSP saturably and in an ion-dependent manner. The calculated binding constant was 0.3 #M or 2.3 times more favorable than the binding interaction of TSP with GPIa-IIa, a high affinity TSP binding protein in platelets (41) . The binding interaction did not involve RGD sequences because no significant binding was observed on GRGDS or fibronectin. The observation that heparin inhibited the interaction between the CSVTCG binding protein and TSP suggests that sulfated glycoconjugates may be involved in the binding interaction. It is possible that CSVTCG and adjacent downstream sequences containing arginine could provide secondary conformation dependent heparin binding domains in TSP. In support of this conclusion is the observation that CSVTCR binds heparin (unpublished data). Therefore under in vitro conditions, the CSVTCG-binding protein could function as a binding protein for TSP and the binding interaction could be mediated by sulfated glycoconjugates associated with the purified CSVTCG binding protein.
To determine whether the CSVTCG binding protein functions to bind CSVTCG containing proteins in vivo, CSV-TCG cell association studies were performed. We found that A549 cells bound CSVTCG in a dose-dependent manner. The binding was inhibited by anti-CSVTCG binding protein antibody and CSVTCG was cross-linked to cell-associated CSVTCG binding protein. These experiments further suggest that CSVTCG binding protein functions as a cell surface receptor for proteins containing the CSVTCG sequence.
Further analysis of the CSVTCG binding protein is currently underway. The protein does not cross-react with antibodies against integrins, GPIV, or the laminin receptor (data not shown). Attempts at partial sequence analysis have been unsuccessful due to blocked end groups. This protein may represent a new class of adhesion molecules that could function in the TSP-adhesive interactions operative during cellmatrix interactions and during the pathogenesis of tumor cell metastasis.
